Keisuke Tomii

Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial

Kazuhiko Nakagawa, Edward B. Garon, Takashi Seto et al. · The Lancet Oncology · 2019 · 594 citations · Full text

Medicine, Pathology, Immune Checkpoint Inhibitor +5

Nintedanib in patients with progressive fibrosing interstitial lung diseases—subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial

Athol U. Wells, Kevin R. Flaherty, Kevin K. Brown et al. · The Lancet Respiratory Medicine · 2020 · 522 citations · Full text

Inbuild Trial, Parallel-group Trial, Advanced Lung Disease +5

Early Immune-Related Adverse Events and Association with Outcome in Advanced Non–Small Cell Lung Cancer Patients Treated with Nivolumab: A Prospective Cohort Study

Shunsuke Teraoka, Daichi Fujimoto, Takeshi Morimoto et al. · Journal of Thoracic Oncology · 2017 · 368 citations · Full text

Oncology, Cancer Epidemiology, Cancer Management +9

Phase III Study, V-15-32, of Gefitinib Versus Docetaxel in Previously Treated Japanese Patients With Non–Small-Cell Lung Cancer

Riichiroh Maruyama, Yutaka Nishiwaki, Tomohide Tamura et al. · Journal of Clinical Oncology · 2008 · 364 citations · Full text

An infectivity-enhancing site on the SARS-CoV-2 spike protein targeted by antibodies

Yafei Liu, Wai Tuck Soh, Jun-ichi Kishikawa et al. · Cell · 2021 · 285 citations · Full text

Vaccine Target, Viral Pathogenesis, Immunology +7